Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:**\n4-Oxoretinol (all-trans) is a naturally occurring retinoid metabolite of all-trans-retinol (vitamin A), in which the hydrogens at position 4 are replaced by an oxo group. It acts as a biologically active signaling molecule and has been shown to function as an antineoplastic agent. Mechanistically, it binds to and activates transcription of the retinoic acid receptors (RARs), but not the retinoid X receptors (RXRs). This activation leads to regulation of gene expression involved in cell differentiation and growth arrest, particularly demonstrated in human promyelocytic leukemia cells and F9 embryonic teratocarcinoma cells. Unlike all-trans-retinoic acid, it does not require conversion to an acid moiety for activity and can induce cellular differentiation directly. It also synergizes with interferon-gamma in promoting cell growth arrest[2][3][5][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 4-oxoretinol.